V. L. Chang

ORCID: 0000-0003-4799-2687
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Protease and Inhibitor Mechanisms
  • Advanced Breast Cancer Therapies
  • CNS Lymphoma Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Peptidase Inhibition and Analysis
  • Viral-associated cancers and disorders
  • Liver Disease Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Digestive system and related health
  • Colorectal and Anal Carcinomas
  • Metastasis and carcinoma case studies
  • Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Immune cells in cancer
  • Cutaneous Melanoma Detection and Management
  • Colorectal Cancer Treatments and Studies
  • GDF15 and Related Biomarkers
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Breast Cancer Treatment Studies
  • Healthcare Systems and Public Health
  • Galectins and Cancer Biology
  • Multiple and Secondary Primary Cancers
  • Renal cell carcinoma treatment

Ministry of Health of the Russian Federation
2024

Tambov State University
2018-2023

State Healthcare Institution "Regional Clinical Oncological Dispensary"
2020-2022

Moscow State University of Medicine and Dentistry
2017

Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that catalyze the degradation reactions extracellular matrix components. In humans, 23 enzymes this known, which subdivided into 6 groups based on their structure and substrate types: collagenases, gelatinases, stromelysins, matrilizines, MMP membrane type other MMPs. functions diverse, an imbalance activity may be one etiological factors various diseases. The review considers classification, regulation genetic...

10.18786/2072-0505-2017-45-4-266-279 article EN cc-by Almanac of Clinical Medicine 2017-01-01

Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response survival rates. However, real-world data on treatment patterns clinical outcomes patients with BRAF V600 mutant are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 melanoma, who received TT a setting were not involved trials. collected from twelve medical centers Russia. objective...

10.3390/cancers13112529 article EN Cancers 2021-05-21

A comprehensive analysis of the cell phenotype inflammatory infiltrate tumor stroma represents a promising area molecular oncology. The study not only soluble forms various immunoregulatory molecules, but also their membrane-bound is considered highly relevant. We performed tissue and circulating PD-1 PD-L1 proteins, as well macrophage B-cell markers in gastric cancer, to assess clinical prognostic significance. blood plasma samples from 63 cancer patients were studied using ELISA...

10.32607/actanaturae.11753 article EN cc-by Acta Naturae 2023-01-20

Results of comparative ELISA investigation pretreatment sPD-1 and sPD-L1 content in blood plasma 100 gastric cancer patients at various disease stages aged 25 to 81 years are presented. Control group included 60 practically healthy donors 18 - 68 years. Plasma concentrations did not differ between control group, levels were statistically significantly lower than (p<0.0001). Positive correlation (R=0.38; p=0.003) was revealed negative (R= -0.26; p=0,009) patients. ROC curve the best...

10.18821/0869-2084-2020-65-6-347-352 article EN Russian Clinical Laboratory Diagnostics 2020-05-15

Analysis of long-term treatment results 101 primary gastric cancer patients at various stages the tumor process followed during 1 - 41 months (median 6,4 months) from onset specific are presented depending on levels soluble forms (s) PD-1 receptor and its ligand PD-L1 in blood plasma. Overall survival assessed by Kaplan-Meyer analysis with help Cox multiparametric regression model was applied as criterion prognostic value. It found that high (≥ 35 pg/ml) sPD-L1 plasma, overall statistically...

10.51620/0869-2084-2021-66-3-139-146 article EN Russian Clinical Laboratory Diagnostics 2021-03-30
Tatyana N. Sokolova Tatyana I. Solov'eva Svetlana N. Aleksakhina M. B. Bolieva V. Е. Goldberg and 79 more Marianna V. Kibisheva К. V. Menshikov Dmitrii V. Ryazanov Aleksandr V. Shkradyuk Yana S. Chapko Anna A. Shchukina Idris M. Khabriev Dmitrii V. Kirtbaya Alexey M. Degtyarev Aleksandr A. Epkhiev Yana A. Tyugina Aleksandr V. Togo Mirza A. Murachuev Aglaya G. Ievleva Evgenii N. Imyanitov A. A. Grechkina Alena S. Stel'makh Svetlana V. Odintsova Grigorii A. Janus Khedi S. Musaeva V. L. Chang A. V. Fateeva Ekaterina P. Startseva Н. О. Попова Yulia Vsevolodovna Mikheeva Anna Vasilevskaya Victoria S. Barbara Petimat I. Khabibulaeva Alina Khlobystina Ludmila V. Bembeeva Vladimir I. Vladimirov Oleg L. Petrenko Natalia G. Ruskova Ekaterina L. Serikova Ksenia S. Subbotina Svetlana A. Tkachenko D. Yu. Yukalchuk Elena Basova M Stepanova Sanal P. Erdniev А. Yu. Goryainova M. I. Gluzman Р. В. Орлова Anastasiya I. Stukan Р. А. Зуков Alena V. Zyuzyukina Yulia N. Murunova А. В. Султанбаев Elena N. Vorobeva Leonid M. Mikhaevich Anna N. Lysenko Z. K. Khachmamuk Andrey E. Kozlov S. Yu. Bakharev Victoria N. Pyliv Irina K. Amirkhanova Shahen G. Parsyan Elena I. Rossokha Leri D. Osidze Irina S. Shumskaya A. V. Agaeva Tatiana A. Kasmynina Veronika V. Klimenko Kamila T. Akhmetgareeva A. A. Vakhitova Madina D. Chakhkieva Yana A. Udalova В. Н. Дмитриев Yana I. Bakshun Alexey E. Vasilyev Gasimly Dunya D Nadezhda A. Kravchenko Dmitriy A. Maksimov Alfia I. Nesterova Zaur M. Khamgokov Ineza O. Sharvashidze Christina H. Gadzaova Galina G. Rakhmankulova Kseniya A. Shvaiko

Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...

10.26442/8151434.2022.1.201435 article EN Journal of Modern Oncology 2022-04-30

Introduction. Despite advances in the diagnosis and drug therapy of some cancers over past decade, solid tumors, particularly gastric cancer, still have a poor prognosis remain leading cause death worldwide. Therefore, development methods for timely diagnosis, identification new targets biochemical factors is an urgent problem clinical oncology. In recent years, focus attention has been on immune checkpoint receptors ligands that can identify patients immunotherapy. The prognostic...

10.17650/2949-5857-2024-14-4-86-92 article EN cc-by Surgery and Oncology 2024-11-30

8090%. The identification of gene mutation profile non-small cell cancer allows to make a molecular portrait, which plays the crucial role in choosing targeted therapy with tyrosine kinase inhibitors.
 aimis study frequency and spectrum activating mutations lung Tambov region.
 presence main driver profile: EGFR, ALK, BRAF, ROS1 PDL-1 using sections paraffin-embedded after surgery biopsy 238 patients help polymerase chain reaction immunohistochemistry. age ranged from 28 years 82...

10.26442/18151434.2020.3.200393 article EN Journal of Modern Oncology 2020-11-30

e14536 Background: Hepatocellular carcinoma (HCC) incidence is increasing in the United States. We compared outcome of HCC patients (pts) over two consecutive decades for a VA population. Methods: In an IRB-approved protocol, we reviewed records pts with diagnosis (dx) seen at Medical Center from 1/1/1990 to 12/31/2009. Demographics, Vietnam era (V) status, stage, alpha-fetoprotein (AFP) level dx, hepatitis B (HBV) and C (HCV), heavy alcohol use (E), tobacco (T), BMI, diabetes (DM), ferritin...

10.1200/jco.2011.29.15_suppl.e14536 article EN Journal of Clinical Oncology 2011-05-20

The article presents a literature review considering epidemiological aspects of secondary cancer the thyroid gland. authors’ clinical observation renal cell carcinoma metastasis into gland with tumor thrombus internal jugular vein is described. authors emphasize necessity complex diagnostics and treatment carcinoma.

10.17650/2222-1468-2017-7-1-91-96 article EN cc-by Head and neck tumors (HNT) 2017-01-01

Background: Over the last 10 years incidence of gastric cancer has declined significantly. Nevertheless, it remains one most prevalent malignancies both in Russia and worldwide. Therefore, problems early diagnostics, prognosis individualized treatment choice are still on agenda. Much attention is paid to evaluation molecular biological characteristics tumor, as well development multiparametric prognostic systems for based its identified characteristics. An important place among potential...

10.18786/2072-0505-2018-46-4-323-329 article EN cc-by Almanac of Clinical Medicine 2018-09-26

Aim. To study the quality of life and symptoms, to assess clinical effect treatment safety in relapsed/refractory classical Hodgkin’s lymphoma (r/r cHL) patients treated with brentuximab vedotin (BV) as > 3rd-line therapy context real practice. Materials & Methods. The enrolled 62 r/r cHL after second- subsequent-line chemotherapies, who are either ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) at time their enrollment into or failure high-dose...

10.21320/2500-2139-2022-15-1-42-53 article EN cc-by-nc Clinical oncohematology 2022-01-01

Stomach cancer is one of the most common tumors gastrointestinal tract. In Russia, stomach ranked fourth in incidence among malignancies and gives ground for lung, breast colon cancers. Although success PD-1/PD-L1 inhibitors application clinical practice has been proven cases many forms malignancies, advantages these types drugs not yet determined. The purpose this review to analyze modern studies concerning significance PD-1 PD-L1 expression find prospects immunotherapy tumors. large number...

10.26442/18151434.2021.1.200749 article EN Journal of Modern Oncology 2021-05-19
Coming Soon ...